Fig. 4.

The ADRB3 agonist promotes thermogenic phenotypes in viperin KO mice. WT and viperin KO mice were administrated i.p. with CL-316243, an ADRB3 agonist (1 mg/kg body weight/d) for 3 d. (A–F) Heat production rates (n = 6; indirect calorimetry) (A), i.p. glucose tolerance test (n = 6) (B), gross weight of adipose tissues (n = 6) (C), relative mRNA levels of thermogenesis- and fatty acid β-oxidation–related genes in the adipose tissues (n = 6) (D), protein expression levels of viperin and UCP1 in iWAT (n = 3) (E), and immunohistochemical staining for UCP1 in adipose tissues (Scale bar: 200 μm) (F) of CL-treated mice. Data are represented as mean ± SEM of biologically independent samples. *P < 0.05; **P < 0.001 vs. WT for the same treatment.